On October 6, 2025, Regeneron Pharmaceuticals announced an expected $83 million charge for acquired research and development, impacting Q3 2025 earnings by approximately $0.68 per share. This charge is primarily related to an $80 million payment to Hansoh Pharmaceuticals.